



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Marit J. van Gils
m.j.vangils@amsterdamumc.nl
Steven W. de Taeye
s.w.detaeye@amsterdamumc.nl

SPECIALTY SECTION
This article was submitted to
B Cell Biology,
a section of the journal
Frontiers in Immunology

RECEIVED 07 November 2022
ACCEPTED 09 November 2022
PUBLISHED 22 November 2022

CITATION
Schriek AI, van Haaren MM,
Poniman M, Dekkers G, Bentlage AEH,
Grobben M, Vidarsson G, Sanders RW,
Verrips T, Geijtenbeek TBH, Heukers R,
Kootstra NA, de Taeye SW and van
Gils MJ (2022) Corrigendum: Anti-
HIV-1 nanobody-IgG1 constructs
with improved neutralization potency
and the ability to mediate Fc
effector functions.
Front. Immunol. 13:1091668.
doi: 10.3389/fimmu.2022.1091668

COPYRIGHT
© 2022 Schriek, van Haaren, Poniman,
Dekkers, Bentlage, Grobben, Vidarsson,
Sanders, Verrips, Geijtenbeek, Heukers,
Kootstra, de Taeye and van Gils. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions

Angela I. Schriek¹, Marlies M. van Haaren¹,
Meliawati Poniman¹, Gillian Dekkers², Arthur E. H. Bentlage³,
Marloes Grobben¹, Gestur Vidarsson³, Rogier W. Sanders^{1,4},
Theo Verrips^{5,6}, Teunis B. H. Geijtenbeek⁷, Raimond Heukers²,
Neeltje A. Kootstra⁷, Steven W. de Taeye^{1*}
and Marit J. van Gils^{1*}

¹Department of Medical Microbiology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, Netherlands, ²QVQ Holding BV, Utrecht, Netherlands,

³Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, United States,

⁵Department of Biology, Faculty of Sciences, Utrecht University, Utrecht, Netherlands, ⁶VerLin BV, Utrecht, Netherlands, ⁷Department of Experimental Immunology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Amsterdam, Netherlands

KEYWORDS

HIV-1, nanobodies, neutralization, Fc fusion, Fc-mediated effector functions

A corrigendum on

Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions

by Schriek AI, van Haaren MM, Poniman M, Dekkers G, Bentlage AEH, Grobben M, Vidarsson G, Sanders RW, Verrips T, Geijtenbeek TBH, Heukers R, Kootstra NA, de Taeye SW and van Gils MJ (2022) *Front. Immunol.* 13:893648. doi: 10.3389/fimmu.2022.893648

In the published article, there was an error in the Funding statement. The funder was mentioned as AIDSfonds and Aids fonds instead of Aidsfonds. The correct Funding statement appears below.

Funding

This work was supported by HealthHolland/Aidsfonds: LSHM19101/P-44802, by HealthHolland/AMC: 2019-1167 and the AMC Fellowship from Amsterdam UMC received by MJG. ST is supported by Young investigator grant P-53301 Aidsfonds.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.